-

Niche Group Advances India's Vision Across Organic Farming and Cancer Treatment
At the same time, he revealed that Niche Agriculture and Pharmaceuticals Limited (NAPL) is working on affordable medicines for diseases such as cancer, epilepsy, and Alzheimer’s. Hundreds of PhD scholars were also interviewed and selected for opportunities during the event. Nestled amidst the beauty of nature, the auditorium of CSKHPKV transformed into far more than…
-

Morepen Labs Q4 Net Profit Rises 69 percent; CDMO Program Moves into Commercial Execution; Board Proposes a Dividend of 10 percent for FY 2025-26
Gurugram, Haryana, India Morepen Laboratories Limited reported strong Q4 FY26 performance with net profit rising 69% YoY to Rs. 20 crore and gross revenue increasing 22% YoY to Rs. 472 crore. Revenue growth during the quarter was supported by export momentum and expansion in the Medical Devices business, while operational momentum strengthened toward the latter…
-
Precede Biosciences Presents New ASCO 2026 Data Demonstrating Ability of Precede Bio Insight™ to Decode MET-Driven Biology and Resistance in Advanced NSCLC
Data include assessment of MET expression, tumor and immune pathway activity, and lineage plasticity from just 1 mL of plasma in advanced NSCLC Plasma MET test showed high concordance with tissue IHC/FISH in EGFR-mutated NSCLC following progression on first-line targeted therapy (AUC=0.97) Baseline and longitudinal profiling in METex14 skipping NSCLC identified biology associated with therapeutic…
-
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancer In head and neck cancer, IMA401 treatment at recommended Phase 2 dose (RP2D) with or without pembrolizumab resulted in a 29% confirmed ORR (4/14), 64% DCR (9/14) and mDOR…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.





